mitoq
AssetSmall moleculeAlso Mitoquinone mesylate
Mitochondria-targeted antioxidant that reduces mitochondrial oxidative stress.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- Indications
- 3
- Trials
- 16
- Developers
- 1
Indications
3Chronic hepatitis c
Phase 2COMPLETEDNCT00433108clinicaltrials.gov7 Oct 2026
Non-alcoholic fatty liver disease
Phase 2TERMINATEDNCT01167088clinicaltrials.gov7 Oct 2026
Parkinson's disease
Phase 2COMPLETEDNCT00329056clinicaltrials.gov7 Oct 2026
- Targets and what it contains1
- Owner and partners1
- Trials16
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 4 sources